HDAC6 siRNA inhibits proliferation and induces apoptosis of HeLa cells and its related molecular mechanism

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3367-3371

  Qin, Hai Xia ^a,b   Cui, Hong Kai ^b   Pan, Ying ^c   Yang, Jun ^b   Ren, Yan Fang ^b   Hua, Cai Hong ^b   Hua, Fang Fang ^b   Qiao, Yu Huan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b The Third Hospital of Xinxiang Medical University   (China)

^c XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Cell apoptosis; Cell proliferation; Histone deacetylase 6; Molecular target; RNA interference

Indexed keywords

EID: 84873593533     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3367     Document Type: Article

References (25)

1. Bazzaro M, Lin Z, Santillan A, et al. (2008). Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res, 14, 7340-7.
2. Bertos NR, Gilquin B, Chan GK, et al. (2004). Role of the tetradecapeptide repeat domain of human histone deacetylase 6 in cytoplasmic retention. J Biol Chem, 279, 48246-54.
3. Kawiak J, Hoser G, Skorski T (1998). Apoptosis and some of its medical implications. Folia Histochem Cytobiol, 36, 99-110.
4. Knudson AG (2001). Two genetic hits (more or less) to cancer. Nat Rev Cancer, 1, 157-62.
5. Kong X, Lin Z, Liang D, et al. (2006). Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol, 26, 2019-28.
6. Kouzarides T (1999). Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev, 9, 40-8.
7. Lehrmann H, Pritchard LL, Harel-Bellan A (2002). Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res, 86, 41-65.
8. Liu Y, Martindale JL, Gorospe M, Holbrook NJ (1996). Regulation of p21WAF1/CIP1 expression through mitogenactivated protein kinase signaling pathway. Cancer Res, 56, 31-5.
9. Mehnert JM, Kelly WK (2007). Histone deacetylase inhibitors: biology and mechanism of action. Cancer J, 13, 23-9.
10. Nakatani F, Tanaka K, Sakimura R, et al. (2003). Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem, 278, 15105-15.
11. Park SW, Kim HS, Yoo NJ, Lee SH (2011). Mutational analysis of mononucleotide repeats in HDAC4, 5, 6, 7, 9 and 11 genes in gastric and colorectal carcinomas with microsatellite instability. Acta Oncol, 50, 317-8.
12. Parkin DM, Pisani P, Ferlay J (1999). Global cancer statistics. CA Cancer J Clin, 49, 33-64.
13. Pecorelli S, Pasinetti B, Angioli R, Favalli G, Odicino F (2005). Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium. Cancer Chemother Biol Response Modif, 22, 515-44.
14. Richon VM, Garcia-Vargas J, Hardwick JS (2009). Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett, 280, 201-10.
15. Ropero S, Esteller M (2007). The role of histone deacetylases (HDACs) in human cancer. Mol Oncol, 1, 19-25.
16. Sadeghi M, Süsal C, Daniel V, et al. (2007). Short communication: decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy. AIDS Res Hum Retroviruses, 23, 886-90.
17. Sakuma T, Uzawa K, Onda T, et al. (2006). Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol, 29, 117-24.
18. Subramanian C, Jarzembowski JA, Opipari AW Jr, Castle VP, Kwok RP. (2011). HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma. Neoplasia, 13, 726-34.
19. Verdel A, Curtet S, Brocard MP, et al. (2000). Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the cytoplasm. Curr Biol, 10, 747-9.
20. Waga S, Hannon GJ, Beach D, Stillman B (1994). The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature, 369, 574-8.
21. Xu X, Xie C, Edwards H, et al. (2011). Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. PLoS One, 6, e17138.
22. Zhang H, Hannon GJ, Beach D (1994). p21-containing cyclin kinases exist in both active and inactive states. Genes Dev, 8, 1750-8.
23. Zhang W, Kone BC (2002). NF-kappaB inhibits transcription of the H(+)-K(+)-ATPase alpha(2)-subunit gene: role of histone deacetylases. Am J Physiol Renal Physiol, 283, F904-11.
24. Zhang Y, Gilquin B, Khochbin S, Matthias P (2006). Two catalytic domains are required for protein deacetylation. J Biol Chem, 281, 2401-4.
25. Zhang Z, Yamashita H, Toyama T, et al. (2004). HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res, 10, 6962-8.